Zoe June Assaf
Senior Director, Cancer Genomics & Emerging Technologies Revolution Medicines
Zoe is a leader in translational medicine, with extensive experience driving the development of biomarker, technology, and computational strategies in oncology clinical development.
Her expertise includes integrating NGS-based technologies and advanced analytics into Phase I/II through registrational Phase III clinical trials, accelerating drug development and maximizing insights from biomarker programs.
She also brings deep experience in liquid biopsy and ctDNA applications, including prospective patient selection for clinical trials, treatment response monitoring to enable go/no-go decision making, and the identification of predictive and prognostic biomarkers to advance key translational medicine objectives.
Seminars
Discover how biopharma researchers and clinical oncologists are harnessing the power of novel epigenomic biomarkers to pinpoint the right patients most likely to benefit from your therapy refining your therapeutic strategies and ultimately bringing more effective medicine to the patients who need them.
- What evidence and study designs are most critical to clinically validate liquid biopsies as early endpoints in trials, and how do these differ across indications?
- How can validated liquid biopsy endpoints improve patient selection and ongoing monitoring to accelerate therapeutic development and decision-making?
- Considerations into choosing the right test for the right applications.
